Clinical Trial

Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients

Study acronym: REVISE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2026-02-27
Trial Details
NCT Number NCT07303296
Lead Sponsor GenSight Biologics
Conditions Leber Hereditary Optic Disease
Enrollment 14 participants
Start Date 2026-01-22
Primary Completion 2028-05-15 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-02